RxDoctor Payments Data

Christopher McCracken, MD

Family Medicine · Boone, NCNPI 1154567915

Payments from drug & device makers

$499in general payments, 2019–2025

Across 31 payments — averaging $16.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$201
  • Pfizer$78
  • GSK$53
  • AstraZeneca$39
  • Teva Pharmaceuticals USA, Inc.$35
  • Amgen$34
  • plus $59 from 4 others

What the payments were for

  • Food & beverage$499100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$499 in reported general payments places this provider in the 55th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$129,457
Medicare patients
394
Services billed
1,893

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban125$154,364
MounjaroTirzepatide96$107,324
TrulicityDulaglutide83$97,260
JanuviaSitagliptin Phosphate41$51,922
OzempicSemaglutide50$47,790
XareltoRivaroxaban40$44,254
GlyxambiEmpagliflozin/Linagliptin24$36,215
JardianceEmpagliflozin32$33,892
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog24$29,255
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog26$27,064
Spiriva HandihalerTiotropium Bromide27$26,103
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$23,393
RybelsusSemaglutide24$21,952
BelsomraSuvorexant29$21,734
Tresiba Flextouch U-100Insulin Degludec29$21,437

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$78$154,364125 claims
MerckJanuvia, Belsomra$15$73,65670 claims
Novo NordiskOzempic, Rybelsus$201$69,74274 claims
GSKTrelegy Ellipta, Breo Ellipta$53$33,80341 claims
AstraZenecaSymbicort$39$15,10936 claims
Astellas Pharma US IncMyrbetriq$13$9,22614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Boone

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →